Seed Stage Biotech Investors: Who Funds the Earliest Science
Raising seed capital for a biotech startup is fundamentally different from raising for software. The capital requirements are higher, timelines to value inflection are longer, and investors need deep scientific literacy to evaluate risk. The pool of investors willing to write seed checks into biotech is narrower than in tech—but it is growing.
The Landscape in Numbers
NFX Signal tracks over 3,600 investors who have participated in biotech seed rounds, though the actively deploying core is significantly smaller. BioCentury identified Novo Holdings, Eli Lilly, and OrbiMed as the most active seed and Series A investors in 2025, each with 11+ disclosed deals. The concentration of capital at the top is significant—the largest funds like ARCH Venture Partners (which raised $3 billion for its 13th fund in 2024) operate at a scale that dwarfs most seed-focused vehicles.
Three Models of Seed Biotech Investing
- Venture Creation Firms
- Atlas Venture, Flagship Pioneering, and Third Rock Ventures don't just invest—they build companies from scratch. Atlas describes its model as \"seed-led venture creation,\" spinning out startups from academic labs with dedicated entrepreneurs-in-residence. Flagship has created over 100 companies through its Pioneering Medicines initiative.
- Biotech Accelerators
- IndieBio (backed by SOSV) deploys from a $306M core fund, writing initial checks of $200K–$500K and providing lab space. Y Combinator has also expanded into biotech, having backed companies like Ginkgo Bioworks and Solugen at the earliest stages.
- Generalist Funds with Bio Theses
- Andreessen Horowitz launched its dedicated Bio + Health fund, backing companies like Octant Bio and Scribe Therapeutics. Khosla Ventures maintains a dedicated $400M seed fund for high-risk scientific bets.
Geographic Concentration
Boston/Cambridge remains the dominant hub for biotech seed capital. Atlas Venture, Third Rock Ventures, and Flagship Pioneering are all headquartered there, with proximity to MIT, Harvard, and the Longwood Medical Area creating a dense ecosystem. San Francisco and the Bay Area host the second cluster, anchored by 5AM Ventures, IndieBio, and the generalist funds on Sand Hill Road.
What Seed Investors Look For
| Factor | What Matters |
|---|---|
| Science | Differentiated mechanism of action, strong IP position, published data |
| Team | Scientific founder credibility, ability to recruit a CEO or CSO |
| Market | Clear patient population, unmet medical need, path to clinical validation |
| Capital Efficiency | Defined milestones achievable with seed capital (typically 18–24 months of runway) |